Cancer Deaths Drop, With Liver Cancer the Exception

The report found higher death rates from liver cancer among the age group most at risk for hepatitis C virus, those born between 1945 and 1965. But increased rates of diabetes, obesity, and alcohol use are to blame for rising liver cancer deaths as well.

Death rates from cancer continue to drop in the United States, with one troubling exception: more people are dying from liver cancer.

This shift is due to increased levels of diabetes, obesity, alcohol abuse, and the effects of hepatitis C virus, according to data released today by CDC, the National Cancer Institute, and the American Cancer Society.

The annual Report to the Nation on the Status of Cancer, issued each year since 1975, had mostly good news: an ongoing decline in cancer incidence has come from decades of progress in preventing the disease, especially in getting Americans to quit smoking.

While lung cancer remains the leading cause of cancer death in both men and women, rates are dropping. New therapies are improving treatment in lung cancer and other forms of the disease, and vaccines may prevent other cancers entirely.

But between 2008 and 2012, liver cancer incidence rose an average of 2.3% each year, and the death rate from liver cancer rose by an average of 2.8% each year among men, and 3.4% each year among women.

This occurred while overall cancer death rates fell 1.5% per year from 2003 to 2012.

Today’s report has some overlap with the stunning findings released in November 2015 by Princeton economists Angus Deaton, FBA, and Anne Case, PhD, who analyzed years of mortality and morbidity data to find a sharp increase in the death rates of lower-income whites with poor education. This cohort had frequent problems with substance abuse, alcohol, chronic liver disease, cirrhosis, and higher rates of suicide.

Across all racial and ethnic groups, women were twice as likely to be diagnosed with the disease, with Native Americans and Alaskans and Asians/Pacific Islanders were most at risk. (This last group is vulnerable to hepatitis B virus infection, which fortunately is decreasing due to vaccination.)

The connection between hepatitis C (HCV) and liver cancer was clear, with death rates from liver cancer highest among those born between 1945 and 1965—this group has 6 times the risk of HCV infection of other adults. Just over 20% of the common liver cancers are linked to HCV infection.

Both CDC and the US Preventive Services Task Force recommends that every person in this age group be screen at least once for the disease, so that treatment can begin before complications emerge. That recommendation is controversial with health plans because treatment is costly: the first cure, Sovaldi, hit the market at $1000 a day for a 12-week course; while competitors have emerged, none are inexpensive.

But experts said the therapies and knowledge exists to combat liver cancer if the will exists.

“We have the knowledge and tools available to slow the epidemic of live cancer in the United States, including testing and treatment for HCV, hepatitis B vaccination, and lowering obesity rates,” said Otis W. Brawley, MD, chief medical officer for the American Cancer Society. “We hope this report will help focus needed attention and resources on liver cancer.

Besides strains of hepatitis, lifestyle factors are playing a role in the rise of liver cancer deaths. Many may realize that alcohol can lead to cirrhosis, or scarring, of the liver, but fewer know that obesity and diabetes can do the same thing.

The Report to the Nation is a collaboration by the CDC, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries.

Related Videos
Screenshot of Sancy Leachman, MD, PhD, smiling
Manmeet Ahluwalia, MD, MBA.
Nicolas Ferreyros, BA, managing director, The Community Oncology Alliance
Susan Sabo-Wagner, MSN, RN, OCN, Oncology Consultants
Samyukta Mullangi, MD, MBA.
Manmeet Ahluwalia, MD, MBA.
Jeff Hunnicutt, CEO, Highlands Oncology Group
Sigrun Hallmeyer, MD, Advocate Health
Kevin Davies, PhD, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center
Related Content
© 2023 MJH Life Sciences
All rights reserved.